Clinical Oncology

[Foreword]

A szerkesztők

DECEMBER 10, 2016

Clinical Oncology - 2016;3(04)

COMMENTS

0 comments

Further articles in this publication

Clinical Oncology

[Reminiscences of a Peer – Remembering Sándor Eckhardt]

KERPEL-FRONIUS Sándor

Clinical Oncology

[News from the World]

Clinical Oncology

[Side-effects of immunotherapy]

LANDHERR László

[The immune system has an important role in controlling and eradicating cancer cells. Antibody therapy against several negative immunologic regulators (checkpoints) has demonstrated promise in a variety of malignancies. The immune checkpoint blockade with antibodies against cytotoxic T lymphocyte- associated antigen 4 (CTLA-4) and the programmed cell death protein 1 pathway (PD-1/PD-L1) and its ligand have a unique and distinct pattern of adverse events. Immune-related adverse events are most commonly observed in the skin, gastrointestinal tract, liver and the endocrine system. Early recognition and treatment are believed to be important in mitigating severity of such adverse effects.]

Clinical Oncology

[Chemotherapy of multiple myeloma]

MIKALA Gábor, CEGLÉDI Andrea, CSACSOVSZKI Ottó, SZEMLAKY Zsuzsanna, PETŐ Mónika

[Multiple myeloma is a multifaceted haematological disease, a plasma cell malignancy that may pose an oncological differential diagnostic challenge. The importance of this disease is emphasized by its incidence. Since there are multiple novel therapies available for myeloma patients, decade-long survival in not uncommon; therefore, myeloma patients provide a signifi cant part of the patients referred to hematological clinics. In this review, fi rst the novel diagnostic criteria are introduced, followed by the standard therapeutic approaches for transplant-eligible and ineligible patients. As the disease nearly always relapses, the later line therapies available in this malignancy are presented with a special emphasis on the Hungarian haematological practice.]

Clinical Oncology

[Long-term central venous access devices in oncology]

PAJKOS Gábor

[Long-term central venous access devices are essential in the management of oncology patients, as they minimize the discomfort caused by frequent venipuncture and cannulation. Indications of application of central venous accesses, possibilities of implantations, immediate and long term complications, they prevention and obviation has been reported based on guidelines and relevant publications. Long term implantable central venous accesses handled by well-trained and exercised team, working with principles of maintenance, these manipulations are effective and safe, therefore suitable in oncological practice.]

All articles in the issue

Related contents

Clinical Oncology

[Foreword]

A szerkesztők

Clinical Oncology

[Foreword]

Clinical Oncology

[Foreword]

AZ MKOT vezetősége

Clinical Neuroscience

[FOREWORD TO THE PROCEEDINGS OF THE “SELYE SYMPOSIUM - 2013”, HELD AT THE HUNGARIAN ACADEMY OF SCIENCES, BUDAPEST, HUNGARY, MAY 8, 2013]

SOMOGYI Árpád, SZABÓ Sándor, ROGER Guillemin,

Clinical Neuroscience

[Foreword]

SOMOGYI Árpád, SZABÓ Sándor, ROGER Guillemin, VOLKER Jahnke, MILAGROS Salas-Prato, YVETTE Taché, LÁZÁR György, GYIRES Klára, VÉCSEI László, HORVÁTH Zoltán, TUKA Bernadett, DUNAI Magdolna, ET al.